Sol-gel announces pipeline update and future development plans

Ness ziona, israel, june 28, 2021 (globe newswire) -- sol-gel technologies, ltd. (nasdaq: slgl), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced positive pre-clinical data for sgt-510, its investigational topical roflumilast drug candidate and provided a corporate update.
SLGL Ratings Summary
SLGL Quant Ranking